Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
75,000
Employees75,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
75,000
Employees75,000

MRK Key Statistics

Market cap
207.88B
Market cap207.88B
Price-Earnings ratio
12.96
Price-Earnings ratio12.96
Dividend yield
3.81%
Dividend yield3.81%
Average volume
11.64M
Average volume11.64M
High today
$84.47
High today$84.47
Low today
$82.65
Low today$82.65
Open price
$84.25
Open price$84.25
Volume
14.49M
Volume14.49M
52 Week high
$120.30
52 Week high$120.30
52 Week low
$73.31
52 Week low$73.31

MRK News

TipRanks 17h
Merck & Company’s Positive Clinical Trial Results and Strategic Positioning Drive Buy Rating

Merck & Company, the Healthcare sector company, was revisited by a Wall Street analyst on August 26. Analyst Daina Graybosch from Leerink Partners maintained a...

Benzinga 1d
Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst

Summit Therapeutics Inc SMMT and Akeso said ivonescimab, a PD-1xVEGF bispecific antibody, can extend patients' lives for EGFR-mutated, locally advanced or metas...

Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst
TipRanks 2d
Merck doses first patient in HERTHENA-Breast04 trial

The first patient has been dosed in the HERTHENA-Breast04 phase 3 trial evaluating the efficacy and safety of investigational patritumab deruxtecan versus inves...

Analyst ratings

58%

of 26 ratings
Buy
57.7%
Hold
42.3%
Sell
0%

More MRK News

Simply Wall St 3d
Merck Unveils New Cardiovascular Research Data at ESC 2025 Congress

is set to present new clinical trial data at the European Society of Cardiology Congress 2025, emphasizing advancements in cardiovascular disease management. Ov...

Merck Unveils New Cardiovascular Research Data at ESC 2025 Congress
Simply Wall St 6d
Merck Valuation in Focus After FDA Breakthrough Therapy Designation for Lung Cancer Drug

Advertisement Most Popular Narrative: 13% Undervalued If you have Merck (MRK) on your watchlist, the latest FDA decision might prompt you to reconsider what i...

Merck Valuation in Focus After FDA Breakthrough Therapy Designation for Lung Cancer Drug
Simply Wall St 7d
Should Breakthrough FDA Status for Novel Lung Cancer Drug Prompt Action From Merck Investors?

Earlier this week, Daiichi Sankyo and Merck announced that ifinatamab deruxtecan received Breakthrough Therapy Designation from the U.S. FDA for adults with ext...

Should Breakthrough FDA Status for Novel Lung Cancer Drug Prompt Action From Merck Investors?
TipRanks 7d
Merck & Co.’s Strategic Positioning and Market Potential Justify Buy Rating Despite Challenges

Analyst Asad Haider of Goldman Sachs maintained a Buy rating on Merck & Company, retaining the price target of $94.00. Elevate Your Investing Strategy: Take adv...

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.
Pfizer
Johnson & Johnson
Chevron
Bristol-Myers Squibb
Eli Lilly
Procter & Gamble
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.